Please use this identifier to cite or link to this item:
https://doi.org/10.1136/bmjgh-2019-edc.37
DC Field | Value | |
---|---|---|
dc.title | OC 8711 Early biomarkers of lung inflammation and function in trials of host-directed tuberculosis therapies (TB-HDT) | |
dc.contributor.author | Wallis, Robert | |
dc.contributor.author | Beattie, Trevor | |
dc.contributor.author | Likoti, Morongwe | |
dc.contributor.author | AHMADOU AHIDJO, BINTOU | |
dc.contributor.author | Edward, Vinodh | |
dc.contributor.author | Rassool, Mohammed | |
dc.contributor.author | Ahmed, Khatija | |
dc.contributor.author | Ginindza, Sibuse | |
dc.contributor.author | Fielding, Katherine | |
dc.contributor.author | Churchyard, Gavin | |
dc.contributor.author | Vangu, Mboyo | |
dc.date.accessioned | 2019-06-18T09:30:25Z | |
dc.date.available | 2019-06-18T09:30:25Z | |
dc.date.issued | 2019-04 | |
dc.identifier.citation | Wallis, Robert, Beattie, Trevor, Likoti, Morongwe, AHMADOU AHIDJO, BINTOU, Edward, Vinodh, Rassool, Mohammed, Ahmed, Khatija, Ginindza, Sibuse, Fielding, Katherine, Churchyard, Gavin, Vangu, Mboyo (2019-04). OC 8711 Early biomarkers of lung inflammation and function in trials of host-directed tuberculosis therapies (TB-HDT). BMJ Global Health 4 (Suppl 3) : A15.2-A15. ScholarBank@NUS Repository. https://doi.org/10.1136/bmjgh-2019-edc.37 | |
dc.identifier.issn | 2059-7908 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/155684 | |
dc.description.abstract | Background : Permanent lung injury and impaired function are common despite TB cure. Host-directed anti-inflammatory therapies may prevent this injury. Early biomarkers of lung inflammation and function can facilitate their evaluation.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In an ongoing study supported by the Bill and Melinda Gates Foundation, HIV-uninfected patients with radiographically moderately or far advanced sputum smear-positive pulmonary tuberculosis receive rifabutin-substituted standard therapy plus either CC-11050 (phosphodiesterase inhibitor), everolimus (mTOR inhibitor), auranofin (gold salt), cholecalciferol, or control, during months 1–4. Study leadership is blinded as to assigned treatments. 18F-fluorodeoxyglucose positron emision tomography (PET) and computed tomography (CT) are performed at baseline and at week 8. Total lung glycolytic activity (SUVbw*ml) and radiodensity (modified HU*ml) are measured using MIM software. Sputum culture, spirometry, 6 min walk test (6MWT), and other biomarkers are performed at multiple time points. Follow-up continues to month 18. This analysis includes only baseline and week 8 data.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Presently, 160/200 participants are enrolled. At baseline, patients have a high burden of infection (median time to detection [TTD] in automated liquid culture 5 days). Median baseline FEV1% of predicted (63%) and 6MWT (402 meters) are typical of moderate to severe chronic lung disease. Baseline TTD, PET, CT, FEV1% and 6MWT are all highly correlated (median rank test p=0.0018). All 5 parameters changed significantly during 8 weeks of treatment (p<0.001). Analysis of adjusted log change from baseline shows PET and CT remain highly correlated (p<0.001), and weakly correlated with FEV1% and 6MWT. TTD shows no correlation with any other endpoint.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Quantitative markers of infection, inflammation, and function are markedly abnormal and highly correlated at baseline in patients with pulmonary tuberculosis. Quantitative CT may substitute for PET as a more readily-performed measure of lung inflammation. The dissociation of microbiologic responses from inflammation and function supports a role for HDTs in TB.</jats:p></jats:sec> | |
dc.publisher | BMJ | |
dc.source | Elements | |
dc.type | Conference Paper | |
dc.date.updated | 2019-06-18T09:11:35Z | |
dc.contributor.department | MICROBIOLOGY AND IMMUNOLOGY | |
dc.description.doi | 10.1136/bmjgh-2019-edc.37 | |
dc.description.sourcetitle | BMJ Global Health | |
dc.description.volume | 4 | |
dc.description.issue | Suppl 3 | |
dc.description.page | A15.2-A15 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Early biomarkers of lung inflammation and function in trials of host-directed tuberculosis therapies (TB-HDT).pdf | Published version | 49.86 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.